Niaspan and simvastatin are two prescribed medicines for treating cholesterol widely. Niaspan is used to raise HDL good cholesterol amounts, and simvastatin is effective in reducing LDL bad cholesterol levels. This combination is being submitted for FDA authorization to handle LDL, HDL and triglycerides in a single pill, which may result in improved patient comfort and outcomes. The Niaspan/simvastatin application includes data from two large clinical studies, made up of a lot more than 1,150 randomized patients, which evaluated safety and efficacy of the combination of Niaspan and simvastatin in patients with mixed dyslipidemia.Whether or not other vendors are willing to make their items interoperable, government frequently overrides industry’s financial passions to achieve a larger public good. I’m all for those who have vision problems. But now I must put my most skilled staff on this problem actually before sorting out the basics of transmitting information. In our iPhone-reverent age group, the dismissal of EHR critics as Luddites is supported by the acknowledgement that systems we once couldn’t imagine we have now can’t live without. However the assumption that EHR development will mirror the cell phone’s trajectory provides three notable flaws. The EHR can be touted as a cost-saving, quality-promoting tool, though cost-saving projections have already been debunked and data on quality are combined.2 Although we’ve made progress in patient safety only by carefully examining our mistakes, somehow the risks posed by technology are expected to right themselves.